Radiopharm Theranostics Statistics
Total Valuation
RADX has a market cap or net worth of $49.62 million. The enterprise value is $24.17 million.
| Market Cap | 49.62M |
| Enterprise Value | 24.17M |
Important Dates
The next estimated earnings date is Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RADX has 3.54 billion shares outstanding. The number of shares has increased by 114.63% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 3.54B |
| Shares Change (YoY) | +114.63% |
| Shares Change (QoQ) | +10.40% |
| Owned by Insiders (%) | 5.59% |
| Owned by Institutions (%) | 7.48% |
| Float | 2.49B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.57 |
| Forward PS | 8.11 |
| PB Ratio | 1.49 |
| P/TBV Ratio | 11.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.01
| Current Ratio | 3.01 |
| Quick Ratio | 3.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -319.11 |
Financial Efficiency
Return on equity (ROE) is -92.10% and return on invested capital (ROIC) is -51.02%.
| Return on Equity (ROE) | -92.10% |
| Return on Assets (ROA) | -28.33% |
| Return on Invested Capital (ROIC) | -51.02% |
| Return on Capital Employed (ROCE) | -54.84% |
| Weighted Average Cost of Capital (WACC) | 8.62% |
| Revenue Per Employee | $775,577 |
| Profits Per Employee | -$2.22M |
| Employee Count | 14 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RADX has paid $91,133 in taxes.
| Income Tax | 91,133 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.47% in the last 52 weeks. The beta is 0.80, so RADX's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | -3.47% |
| 50-Day Moving Average | 4.39 |
| 200-Day Moving Average | 4.86 |
| Relative Strength Index (RSI) | 47.83 |
| Average Volume (20 Days) | 22,985 |
Short Selling Information
The latest short interest is 62,568, so 1.00% of the outstanding shares have been sold short.
| Short Interest | 62,568 |
| Short Previous Month | 43,083 |
| Short % of Shares Out | 1.00% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.51 |
Income Statement
In the last 12 months, RADX had revenue of $10.86 million and -$31.07 million in losses. Loss per share was -$0.01.
| Revenue | 10.86M |
| Gross Profit | -14.82M |
| Operating Income | -27.76M |
| Pretax Income | -31.22M |
| Net Income | -31.07M |
| EBITDA | -26.13M |
| EBIT | -27.76M |
| Loss Per Share | -$0.01 |
Balance Sheet
The company has $23.02 million in cash and n/a in debt, with a net cash position of $23.02 million or $0.01 per share.
| Cash & Cash Equivalents | 23.02M |
| Total Debt | n/a |
| Net Cash | 23.02M |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | 33.31M |
| Book Value Per Share | 0.01 |
| Working Capital | 20.51M |
Cash Flow
| Operating Cash Flow | -24.75M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.70M |
| Net Borrowing | n/a |
| Free Cash Flow | -25.97M |
| FCF Per Share | -$0.01 |
Margins
Gross margin is -136.51%, with operating and profit margins of -255.63% and -286.16%.
| Gross Margin | -136.51% |
| Operating Margin | -255.63% |
| Pretax Margin | -287.54% |
| Profit Margin | -286.16% |
| EBITDA Margin | -240.69% |
| EBIT Margin | -255.63% |
| FCF Margin | n/a |
Dividends & Yields
RADX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -114.63% |
| Shareholder Yield | -114.63% |
| Earnings Yield | -62.62% |
| FCF Yield | -52.34% |
Analyst Forecast
The average price target for RADX is $17.06, which is 298.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.06 |
| Price Target Difference | 298.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 115.63% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RADX has an Altman Z-Score of -2.66 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.66 |
| Piotroski F-Score | 3 |